Vericel Corp VCEL:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:20 PM EDT
43.74UNCH (UNCH)
Volume
45,563
Close
43.74quote price arrow down-0.12 (-0.27%)
Volume
476,443
52 week range
29.24 - 53.05
Loading...
  • Open43.67
  • Day High44.50
  • Day Low42.38
  • Prev Close43.86
  • 52 Week High53.05
  • 52 Week High Date04/01/24
  • 52 Week Low29.24
  • 52 Week Low Date04/25/23

Key Stats

  • Market Cap2.116B
  • Shares Out48.38M
  • 10 Day Average Volume0.31M
  • Dividend-
  • Dividend Yield-
  • Beta1.76
  • YTD % Change22.83

KEY STATS

  • Open43.67
  • Day High44.50
  • Day Low42.38
  • Prev Close43.86
  • 52 Week High53.05
  • 52 Week High Date04/01/24
  • 52 Week Low29.24
  • 52 Week Low Date04/25/23
  • Market Cap2.116B
  • Shares Out48.38M
  • 10 Day Average Volume0.31M
  • Dividend-
  • Dividend Yield-
  • Beta1.76
  • YTD % Change22.83

RATIOS/PROFITABILITY

  • EPS (TTM)-0.07
  • P/E (TTM)-639.47
  • Fwd P/E (NTM)825.28
  • EBITDA (TTM)-1.715M
  • ROE (TTM)-1.52%
  • Revenue (TTM)197.516M
  • Gross Margin (TTM)68.64%
  • Net Margin (TTM)-1.61%
  • Debt To Equity (MRQ)0.04%

EVENTS

  • Earnings Date05/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Vericel Corp

 

Profile

MORE
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone...
Robert Zerbe
Independent Chairman of the Board
Dominick Colangelo
President, Chief Executive Officer, Director
Michael Halpin
Chief Operating Officer
Joseph Mara
Chief Financial Officer
Address
64 Sidney St
Cambridge, MA
02139-4170
United States

Top Peers

SYMBOLLASTCHG%CHG
TGTX
TG Therapeutics Inc
13.78-0.21-1.50%
MOR
MorphoSys AG
17.98-0.07-0.39%
IMCR
Immunocore Holdings PLC
55.68+0.94+1.72%
DNA
Ginkgo Bioworks
0.8649-0.0597-6.4568%
KYMR
Kymera Therapeutics Inc
33.97-1.15-3.27%